Literature DB >> 25520003

Serum Levels of Thioredoxin Are Associated with Stroke Risk, Severity, and Lesion Volumes.

Meng-Hai Wu1, Fang-Yu Song1, Li-Ping Wei1, Zhao-Yun Meng2, Zhi-Qiang Zhang3, Qin-De Qi4.   

Abstract

Oxidative stress increases serum thioredoxin (TRX), a redox-regulating protein with antioxidant activity recognized as an oxidative stress marker. The aim of this study was to assess the clinical significance of serum TRX levels in Chinese patients with acute ischemic stroke (AIS). From January 1, 2012, to December 31, 2013, all patients with first-ever acute ischemic stroke were recruited to participate in the study. Serum levels of TRX were assayed with solid-phase sandwich enzyme-linked immunosorbent assay (ELISA), and the severity of stroke was evaluated with the National Institutes of Health Stroke Scale (NIHSS) score on admission. The results indicated that the median serum TRX levels were significantly (P < 0.0001) higher in stroke patients as compared to normal cases [15.03 ng/mL (interquartile range (IQR), 10.21-32.42) and 8.95 ng/mL (6.79-11.05), respectively]. We found the serum TRX reflected the disease severity of AIS. There was a significant positive association between serum TRX levels and NIHSS scores (r = 0.476, P < 0.0001). After adjusting for all other possible covariates, TRX remained as an independent marker of AIS with an adjusted OR of 1.245 (95 % confidence interval (CI), 1.164-1.352; P < 0.0001). Based on the receiver operating characteristic (ROC) curve, the optimal cutoff value of serum TRX levels as an indicator for auxiliary diagnosis of AIS was projected to be 11.0 ng/mL, which yielded a sensitivity of 80.3 % and a specificity of 73.7 %, with the area under the curve at 0.807 (95 % CI, 0.766-0.847). Further, in our study, we found that an increased risk of AIS was associated with serum TRX levels ≥11.0 ng/mL (adjusted OR 6.99; 95 % CI, 2.87-12.87) after adjusting for possible confounders. Our study demonstrated that serum TRX levels at admission were associated with stroke severity and lesion volumes. Elevated levels could be considered as a novel, independent diagnosis marker of AIS in a Chinese sample.

Entities:  

Keywords:  Acute ischemic stroke; Chinese; Oxidative stress; Risk; Thioredoxin

Mesh:

Substances:

Year:  2014        PMID: 25520003     DOI: 10.1007/s12035-014-9016-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  48 in total

1.  Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke.

Authors:  Fabrizio Montecucco; Sébastien Lenglet; Angèle Gayet-Ageron; Maria Bertolotto; Graziano Pelli; Domenico Palombo; Bianca Pane; Giovanni Spinella; Sabine Steffens; Lizzia Raffaghello; Vito Pistoia; Luciano Ottonello; Aldo Pende; Franco Dallegri; François Mach
Journal:  Stroke       Date:  2010-06-10       Impact factor: 7.914

Review 2.  Potential markers of oxidative stress in stroke.

Authors:  Antonio Cherubini; Carmelinda Ruggiero; M Cristina Polidori; Patrizia Mecocci
Journal:  Free Radic Biol Med       Date:  2005-10-01       Impact factor: 7.376

Review 3.  Redox regulation of cellular activation.

Authors:  H Nakamura; K Nakamura; J Yodoi
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

4.  Oxidative stress in the context of acute cerebrovascular stroke.

Authors:  M M El Kossi; M M Zakhary
Journal:  Stroke       Date:  2000-08       Impact factor: 7.914

Review 5.  Iron, oxidative stress and early neurological deterioration in ischemic stroke.

Authors:  T Carbonell; R Rama
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

6.  A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene.

Authors:  Y Taniguchi; Y Taniguchi-Ueda; K Mori; J Yodoi
Journal:  Nucleic Acids Res       Date:  1996-07-15       Impact factor: 16.971

7.  Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke.

Authors:  Concepción Sánchez-Moreno; John F Dashe; Tammy Scott; David Thaler; Marshal F Folstein; Antonio Martin
Journal:  Stroke       Date:  2003-12-11       Impact factor: 7.914

Review 8.  Thioredoxin as a putative biomarker and candidate target in age-related immune decline.

Authors:  Helen R Griffiths; Stuart J Bennett; Peter Olofsson; Christopher R Dunston
Journal:  Biochem Soc Trans       Date:  2014-08       Impact factor: 5.407

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

10.  An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis.

Authors:  Hedley C A Emsley; Craig J Smith; Carole M Gavin; Rachel F Georgiou; Andy Vail; Elisa M Barberan; John M Hallenbeck; Gregory J del Zoppo; Nancy J Rothwell; Pippa J Tyrrell; Stephen J Hopkins
Journal:  J Neuroimmunol       Date:  2003-06       Impact factor: 3.478

View more
  3 in total

1.  Serum CXCL12 Levels as a Novel Predictor of Future Stroke Recurrence in Patients with Acute Ischemic Stroke.

Authors:  Xiao-Lin Gu; Lin Liu; Xiang-Dong Lu; Zhen-Rui Liu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

Review 2.  Changing Perspectives from Oxidative Stress to Redox Signaling-Extracellular Redox Control in Translational Medicine.

Authors:  Paola Loreto Palacio; José R Godoy; Orhan Aktas; Eva-Maria Hanschmann
Journal:  Antioxidants (Basel)       Date:  2022-06-16

3.  Serum IL-33 Is a Novel Diagnostic and Prognostic Biomarker in Acute Ischemic Stroke.

Authors:  Li Qian; Lin Yuanshao; Huang Wensi; Zhou Yulei; Chen Xiaoli; Wang Brian; Zhang Wanli; Cai Zhengyi; Xue Jie; Zhang Wenhui; Yu Tieer; Wang Hong; He Jincai; Jin Kunlin; Shao Bei
Journal:  Aging Dis       Date:  2016-10-01       Impact factor: 6.745

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.